Cellular immunotherapy targeting kappa myeloma antigen for the treatment of multiple myeloma (AACR 2023)
Chimeric Antigen Receptor (CAR)-T cell therapy has recently entered the standard of care for relapsed and refractory MM, following the recent FDA-approval of two CAR-T cell products, ide-cel® and cilta-cel®, which target the B cell maturation antigen (BCMA)...The monoclonal antibody, KappaMab (MDX-1097), binds to a conformational epitope on KMA, and has been assessed in phase I, IIa and IIb clinical trials in relapse refractory myeloma patients (1)...We successfully generated human anti-KMA CAR-T cells with high and stable CAR expression and a predominately memory T cell phenotype...(1) Spencer et al. Blood Cancer Journal (2019) 9:58